Resumen

OMACOR ® (A concentrated formulation Omega 3 Acid) in the treatment of high triacylglycerols. AVFT [online]. 2014, vol.33, n.1, pp.13-19. ISSN 0798-0264.

Background: Hyperlipidemia is a common condition that promotes atherosclerosis development. Triglycerides are being considered a very important factor. n-3 fatty acids lower triglycerides and have been associated with lower risk of sudden death in patients with myocardial infarction and could be effective in patients without evidence of prior cardiovascular disease. Methods: We performed a prospective, open, multicenter, pharmacovigilance study, to evaluate Omacor^® effectiveness in reducing triglyceride levels. After four weeks with patients underwent diet, we made lipid profile in fasting, measuring triglycerides, total cholesterol, LDL-C, VLDL-C, HDL-C, Non- HDL-C and glucose, AST and ALT. Patient who continued triglycerides above 150 mg/dL were passed to next phase of study with Omacor^®, 1 gr orally, BID for 6 weeks. Results: 185 patients were analyzed by ITT. Treatment with Omacor^® reported a significant decrease in weight, BMI, DBP and SBP (p<0.001). In this study, the effect of treatment significantly reduced all lipid variables studied (CT, HTG, LDL-C, non-HDL-C; p<0.001) with an increase in HDL-C (p 0.002). HTG was reduced by 33% (p<0.001) and non-HDL-C 14% (p<0.001). After treatment, 59.77% achieved with diet plus Omacor^® the target of TG<150mg/dL compared with the 4.47% only diet. Conclusions: The administration of Omacor^® for six weeks in patients with HTG was safe, with a significant decrease in all lipid and glycemic variables.

Palabras clave : Omega 3 fatty acids; Triglycerides; Omacor^®.